bitop Ectoin^® Lozenges improve sore throat symptoms by almost 80 %

Dortmund, February 2019: A recently published study proved that bitop Ectoin^® Lozenges effectively reduce symptoms of acute viral pharyngitis (sore throat) by 79.5 % after only one week of treatment. With this result, they show significant superiority compared to Hyaluronic acid lozenges (GeloRevoice^®) in reducing redness of the mucosa in mouth and throat.

Moreover, the general condition of nearly 70 % of the patients using bitop Ectoin^® Lozenges was rated as “very good” by the physician. In comparison, only 48 % of the patients using GeloRevoice^® and only one fifth of the salt water group reached a “very good” condition.

The tolerability of bitop Ectoin^® Lozenges is significantly superior compared to HA-containing lozenges (physician’s assessment). All patients treated with bitop Ectoin^® Lozenges were highly satisfied with the pleasant wild berry taste. In contrast, 40 % of patients treated with HA-containing lozenges and 45 % of the patients treated with salt water rated the taste of their product as unpleasant.

Here you can download the research paper and the study factsheet.

Interested in a license for bitop Ectoin^® Lozenges? Contact us: bd@bitop.de